• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Microneedle patch, protein combo could boost efficacy of flu vaccine

July 20, 2017 By Sarah Faulkner

microneedle patch booster
Credit: Georgia State University

Researchers at Georgia State University and Georgia Institute of Technology have devised a method to boost the efficacy of a traditional influenza vaccine.

The team combined a fusion protein into a microneedle patch made from a biocompatible polymer. The patch’s needles are biodegradable, releasing vaccine into the skin as they dissolve.

Mice receiving a conventional inactivated vaccine and the microneedle-patch booster better maintained an antibody response against the influenza virus compared to those that received the traditional vaccine alone, according to a study published in the Journal of Controlled Release.

The researchers immunized mice with an inactivated influenza vaccine and, four weeks later, gave them either an intramuscular injection of the fusion protein, the microneedle patch with the protein or a placebo microneedle patch.

Then, the team assessed whether the booster changed the immune response that is triggered by traditional vaccines. The mice were presented with H1N1 and H3N2 influenza viruses and monitored daily, according to the team, for 14 days.

Mice that were given the microneedle patch booster showed greater survival and cellular immune responses compared to those that received a placebo.

“Our study demonstrates that M2e-based vaccines greatly improve immune responses and strengthen protective functions against influenza virus infection,” Baozhong Wang, associate professor at the Institute for Biomedical Sciences at Georgia State, said in prepared remarks. “We found that a skin-applied 4M2e-tFliC microneedle patch boosted immunization to seasonal vaccine recipients and may be a rapid approach to increasing the protective efficacy of seasonal vaccines in response to influenza virus challenges. Thus, the M2e antigen is a promising candidate for the development of universal influenza vaccines.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Preclinical Trials, Research & Development Tagged With: Georgia Institute of Technology, georgiastateuniversity

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS